MEDICAL

AlgaEnergy Agreements with Laboratoire M2 for Distribution and Product Development

AlgaEnergy | January 14, 2021

AlgaEnergy Agreements with Laboratoire M2 for Distribution and Product Development
AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide.

AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for the world's producers. Laboratoire M2's THYMOX® items, gotten from the antimicrobial intensity of thyme oil and other regular oils, are utilized in harvest and indoor farming, just as in turf and nursery markets.

Under the arrangements, AlgaEnergy will acquire restrictive worldwide rights to disperse the THYMOX crop insurance product offering through AlgaEnergy's specialty units in key rural business sectors in Europe, the Americas, Africa and Asia-Pacific. The two organizations likewise marked a permit and collective item advancement understanding under which their logical groups will together attempt to make new, value-added biocontrol products.

Spotlight

Farmers Benefit from Agricultural Biotechnology Seeds. Decades of documented evidence demonstrates that agricultural biotechnology is a safe and beneficial technology that contributes to both environmental and economic sustainability.

Spotlight

Farmers Benefit from Agricultural Biotechnology Seeds. Decades of documented evidence demonstrates that agricultural biotechnology is a safe and beneficial technology that contributes to both environmental and economic sustainability.

Related News

INDUSTRIAL IMPACT

Partek and Agilent Partner to Deliver Alissa Customers End-to-End Bioinformatics Workflow

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow software through the Alissa Portal for a single point solution. “As next-generation sequencing is more broadly adopted for clinical applications, our customers’ software requirements are also expanding. By integrating Partek Flow with the Agilent Alissa Clinical Informatics Platform we will strengthen our overall offering to address diverse applications and workflows across the translational research to clinical testing continuum,” stated Kevin Meldrum, vice president and general manager for the Agilent Genomics Division. About Partek Incorporated Partek Incorporated develops and globally markets quality analysis software and services for life sciences research. Partek software is unique in supporting all major genomic platforms, including bulk and single cell next-generation sequencing. Over eight thousand peer-reviewed scientific papers have used Partek software to streamline the analysis of Gene Expression, miRNA Expression, Copy Number, Allele-Specific Copy Number, LOH, Association, Trio analysis, ChIP-Seq, Single Cell RNA-Seq, RNA-Seq, DNA-Seq, DNA Methylation and qPCR studies. Partek, headquartered in St. Louis, MO, USA, has been turning data into discovery® since 1993.

Read More

CELL AND GENE THERAPY

Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop more effective drugs. Inventia Life Science differentiates from other bioprinting solutions with their RASTRUM™ 3D cell culture platform, which empowers biologists with easy access to reproducible and tunable tissue models at scale. By incorporating liver-specific extracellular matrix (ECM) components developed by Xylyx Bio, the partners are developing robust 3D bioprinted liver tissue models. Inventia will complete product development and offer these solutions for research and drug discovery applications, with plans to expand offerings to other tissue types. Dr. John O'Neill, Xylyx Bio Co-Founder and Chief Scientific Officer, stated: "Xylyx is collaborating with groundbreaking companies like Inventia to lead the industry transition to physiologically relevant disease modeling and compound testing 'in matrico'." Dr. Julio Ribeiro, Co-Founder and Chief Executive Officer of Inventia Life Science, is very enthusiastic about this partnership. He stated, "At Inventia Life Science we strive to provide an automated 3D cell culture solution to accelerate drug discovery and biomedical research. This partnership with Xylyx is a significant step in the right direction in further expanding our matrix portfolio to enable the generation of complex tissue models in a reproducible and tissue specific manner." About Xylyx Bio Xylyx Bio is a pioneer in advanced biomaterials, serving customers across research, clinical and commercial applications. The Company's products provide the full suite of components from the natural cell microenvironment essential for the most accurate and actionable results for scientists working in pharmaceutical development, cell biology research, and regenerative medicine. About Inventia Life Science Inventia Life Science is a fast-growing biotech start-up based in Sydney, Australia, that is revolutionizing biomedical research, drug discovery and regenerative medicine. The award-winning RASTRUM™ 3D cell culture platform has already been adopted in leading medical research institutes and biotechnology and pharmaceutical companies worldwide, which are creating bioprinted tissue models that mimic real human biology.

Read More

INDUSTRIAL IMPACT

Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines using Synthetic Biology

Antheia | August 13, 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo's high throughput enzyme design and screening capabilities to broaden its pipeline of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs). Nearly half of all medicines today are sourced from nature, and many of the most widely used essential medicines are sourced directly from medicinal plants. The World Health Organization classifies "essential medicines" as medicines "that satisfy the priority health care needs of the population." The supply chains for most critical plant-based medicines are fragile, and depend on a years-long process of growing, harvesting, transporting, and processing specialty plants. During times of extreme demand or constrained supply, many plant-based medicines, including widely used analgesics and sedatives, can be in shortage, as was recently the case during the COVID-19 pandemic. "Antheia is committed to using synthetic biology to enable more equitable access to essential medicines," said Kristy Hawkins, CSO and co-founder at Antheia. "By partnering with Ginkgo Bioworks, a global leader in organism engineering, we are greatly increasing our ability to develop essential medicines at the speed and scale necessary to drive change in global pharma supply chains." Synthetic biology platforms, such as those created by Antheia and Ginkgo Bioworks, make it possible for critical medicines to be produced on-demand in a much more efficient and environmentally friendly process compared to today's fragmented production systems. Additionally, when it comes to plant-based pharmaceuticals, biomanufacturing has significant advantages in supply chain resiliency and agility, cost, quality control, sustainability and efficiency compared to the conventional production methods, which are based on crop farming. "We're proud to partner with Antheia, a leader in the application of synthetic biology, as they leverage our platform to produce essential medicines at scale," said Tom Knight, co-founder at Ginkgo Bioworks. "Antheia and Ginkgo are both committed to using biology to build a better future, and we look forward to a long lasting partnership that will drive substantial impact." Antheia is focused on plant-inspired pharmaceuticals that are too complex to be produced through scalable synthetic chemistry processes. Antheia has managed to efficiently produce these highly-complex pharmaceuticals by pioneering whole-cell engineering, a technique that reconstructs multi-step biosynthetic pathways of unprecedented complexity in yeast cells. As Antheia brings its engineered microbes to commercial scale, it continually invests in strain optimization to ensure highly efficient production of the pharmaceutical compound of interest. Through this partnership, Antheia plans to leverage Ginkgo's extensive and rapid cell programming platform and biological codebase to greatly expand and accelerate its strain and enzyme engineering work. "Antheia is at the cutting edge of synthetic biology innovation, and its whole-cell engineering platform is capable of producing entire classes of medicines that were previously inaccessible," said Barry Canton, co-founder and Chief Technology Officer at Ginkgo Bioworks. "We are thrilled that Ginkgo's platform can support innovators like Antheia as they create next generation manufacturing technologies for essential medicines." About Antheia Antheia is unlocking the medicinal power of nature with synthetic biology. Through a novel whole-cell engineering approach to reconstruct complex molecules in yeast, Antheia's platform enables the discovery and manufacturing of plant-inspired drugs of unprecedented complexity and diversity. Antheia's team of scientists and technologists is headquartered in Menlo Park, California.

Read More